Core Viewpoint - The company ST HuLuWa (605199.SH) is facing multiple challenges including expected performance losses, new product approvals, regulatory investigations, and share freezes of its controlling shareholder [1] Group 1: Performance Outlook - The company anticipates a net loss attributable to shareholders in 2025, estimated between -210 million and -310 million yuan, primarily due to industry policy adjustments, market environment changes, increased depreciation from new production facilities, and rising financial costs [2] Group 2: Product Development - The company's wholly-owned subsidiary has received approval from the National Medical Products Administration for the registration of "Compound Polyethylene Glycol Electrolyte Oral Solution," aimed at treating chronic constipation and fecal impaction. Additionally, the company has obtained registration for "Ebastine Oral Solution." These new product approvals are expected to enhance the company's product line, although future sales performance remains uncertain due to policy and market factors [3] Group 3: Regulatory Issues - The company and its chairman Liu Jingping are under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws, with the investigation ongoing. The company faces risks of investor lawsuits due to prior disclosure issues. Following a negative audit opinion on internal controls for the 2024 financial report, the company's stock has been subject to risk warnings (ST) since April 30, 2025. The company has established a special rectification team to address internal control issues [4] Group 4: Shareholder Pledge - A portion of shares held by the controlling shareholder, Hainan HuLuWa Investment Development Co., Ltd., has been judicially frozen, accounting for 5.97% of the total share capital, which may introduce uncertainties regarding the stability of the company's control [5]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the drug registration certificate of Ebastine oral solution, which is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria [1] Group 1 - The full subsidiary of the company, Guangxi Weiwei Pharmaceutical Co., Ltd., is responsible for the newly approved Ebastine oral solution [1] - The Ebastine oral solution is suitable for treating allergic rhinitis (both seasonal and perennial) with or without allergic conjunctivitis, as well as chronic idiopathic urticaria [1]

Group 1 - Tenglong Co., Ltd. has small batch products indirectly applied in data center/server liquid cooling and energy storage liquid cooling fields [1] - Fuyao Glass reported a 37.33% year-on-year increase in net profit for the first half of 2025, reaching 4.805 billion yuan [2] - Huihong Group plans to dispose of certain financial assets, including stocks of Hongye Futures, Zhongtai Securities, and Shengyi Technology, to optimize asset structure [3] Group 2 - Zhongheng Electric clarified that it has not signed cooperation agreements with overseas cloud companies like NVIDIA, Meta, and Google [4] - Kosen Technology announced it does not produce robot products, despite recent stock price fluctuations [5] - Garden Shares stated it does not have a controlling relationship with Yunzhin Technology [6] Group 3 - Yiling Pharmaceutical's new drug application for "Children's Lianhua Qinggan Granules" has been accepted by the National Medical Products Administration [7] - Zhuochuang Information plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [8] - Lianhuan Pharmaceutical's new oral solution production line has passed GMP compliance inspection [9] Group 4 - Xianda Co., Ltd. reported a 2561.58% year-on-year increase in net profit for the first half of 2025, reaching 136 million yuan [10] - Jiangte Motor announced that its subsidiary Yichun Silver Lithium will resume production soon [11] - Dameng Data's board member and general manager is under investigation [12] Group 5 - Dongjie Intelligent is planning a change in control, leading to a suspension of its stock and convertible bonds [13] - Gibit reported a 24.50% year-on-year increase in net profit for the first half of 2025, amounting to 645 million yuan [14] - Wuzhou Special Paper's net profit decreased by 47.57% year-on-year to 122 million yuan [15] Group 6 - Harbin Air Conditioning reported a loss of 7.64 million yuan for the first half of 2025, reversing from profit [16] - Tibet Tourism achieved a net profit of 2.09 million yuan, turning around from a loss of 2.58 million yuan in the previous year [17]

Core Insights - Lianhuan Pharmaceutical (600513.SH) announced that its wholly-owned subsidiary, Lianhuan (Anqing), has received the "Drug GMP Compliance Inspection Notification" from the Anhui Provincial Drug Administration [2] - This inspection is based on the contract manufacturing of Ebastine oral solution (National Drug Approval Number H20243410) and marks the first successful GMP compliance inspection for the newly established oral solution production line [2] - The investment in the oral solution production line amounts to approximately 7.5 million yuan [2]

Group 1 - The company announced that its wholly-owned subsidiary, Lianhuan Pharmaceutical (Anqing) Co., Ltd., received a notice of compliance inspection for drug GMP from the Anhui Provincial Drug Administration [1] - The inspection will focus on the oral solution dosage form, specifically the production line for oral solution No. 1, scheduled from June 4 to June 7, 2025 [1] - The inspection is based on the contract manufacturing of Ebastine oral solution (National Drug Approval No. H20243410) [1] Group 2 - As of the announcement date, the investment in the oral solution production line amounts to approximately RMB 7.5 million [1]